Emcure Pharmaceuticals Ltd

Emcure Pharmaceuticals Ltd announced that its subsidiary, Marcan Pharmaceuticals Inc., has acquired all Class E Special Shares in its step-down subsidiary, Mantra Pharma Inc., for an aggregate consideration of CAD $50 million. The transaction, which occurred on July 02, 2026, ensures Mantra remains a 100% subsidiary of Marcan. Mantra Pharma Inc. is engaged in the marketing and distribution of prescription drugs and natural health products in Canada, with an annual turnover of CAD $96.67 million. This acquisition is considered a related party transaction between two wholly-owned subsidiaries and is being conducted on an arm's length basis. The deal is subject to completion of requisite compliances under Canadian law.

Emcure Pharmaceuticals Ltd has announced that Mr. Kuber Jagdale, President of its API Business, will superannuate from his employment on June 30, 2026. Consequently, he will cease to be a Senior Management Personnel of the company. This departure is due to retirement and not a resignation. The company has provided the necessary disclosures as per SEBI Listing Regulations. Mr. Jagdale's tenure marks the end of an era for the API business leadership.

Emcure Pharmaceuticals Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This closure is in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The trading window will be shut from Wednesday, July 01, 2026, and will reopen 48 hours after the declaration of the company's unaudited financial results for the quarter ending June 30, 2026. The specific date for the board meeting to approve these results will be communicated later. The company has also uploaded this intimation on its website.

The United States Food and Drug Administration (US FDA) conducted a cGMP inspection at Emcure Pharmaceuticals' formulations facility in Sanand, Ahmedabad, Gujarat, from May 6, 2026, to May 15, 2026. At the conclusion of the inspection, the company received a Form 483 with 7 observations, which are procedural in nature. Emcure plans to address these observations comprehensively and respond to the US FDA within the stipulated timeframe.

Emcure Pharmaceuticals Ltd has been assigned an ESG rating of 21 by NSE Sustainability Ratings & Analytics Limited for the financial year 2024-25. The rating, based on publicly available information, was communicated to Emcure via email on May 7, 2026. This disclosure is made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Emcure Pharmaceuticals Ltd. announces the re-appointment of Dr. Mukund Gurjar as Whole-time Director for one year starting August 28, 2026, and Mr. Satish Mehta as Managing Director for five years starting April 1, 2027, subject to shareholder approval. Both directors meet regulatory requirements for holding office.

Emcure Pharmaceuticals Ltd. announces the re-appointment of Dr. Mukund Gurjar as a Whole-time Director for one year starting August 28, 2026, and Mr. Satish Mehta as Managing Director for five years starting April 1, 2027. The re-appointments are subject to shareholder approval. Both individuals meet regulatory requirements for holding their respective positions.

Emcure Pharmaceuticals Ltd's Board of Directors has recommended a final dividend of ₹3.60 per equity share (36%) for the financial year ended March 31, 2026, subject to shareholder approval. The board also approved the re-appointment of Dr. Mukund Gurjar as a Whole-time Director for one year and Mr. Satish Mehta as Managing Director for five years, both subject to member approval at the upcoming Annual General Meeting. Audited financial results for FY26 with an unmodified opinion from the statutory auditors were also approved.

Emcure Pharmaceuticals Ltd. announced its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The results were approved by the Board of Directors in a meeting held on May 5, 2026, following a review and recommendation by the Audit Committee. The financial results and audit reports from B S R & Co. LLP are enclosed.

Emcure Pharmaceuticals Ltd's Board of Directors approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The board recommended a final dividend of ₹3.60 per equity share (36%) subject to shareholder approval. Additionally, Dr. Mukund Gurjar was re-appointed as a Whole-time Director for one year starting August 28, 2026, and Mr. Satish Mehta was re-appointed as Managing Director for five years commencing April 1, 2027, both subject to member approval.